[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Volta Medical\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100641807","volta-medical-ai-software-in-real-world-during-af-ablation-100641807",false,"NCT07621055","VOLta Medical AI-software in REal-World During AF Ablation","Real-World Experience of Volta Medical AI-software During AF Ablation Using Next-generation Mapping and Ablation Technologies","VOLTAIRE-AF","Inclusion Criteria:\n\n1. Patient aged 18 years or older.\n2. Patient candidate for catheter ablation to treat paroxysmal or persistent atrial fibrillation, atrial tachycardia, de novo or after one or several previous ablation procedures, and for which the investigator considers using Volta AF-Xplorer II.\n3. Patient able and willing to provide written informed consent to participate in the study.\n4. Only for France: Patient affiliated to the French social security system.\n\nExclusion Criteria:\n\n1. Contraindication to AF\u002FAT catheter ablation using RF and\u002For PFA.\n2. Patient who is or could potentially be pregnant.\n3. Person deprived of liberty or under guardianship.\n4. Person unable to undergo a medical monitoring for geographical, social or psychological reasons.\n5. Patient's refusal to participate in the study.\n6. Enrollment in a premarket clinical study evaluating device, drug or biologic product.","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","OBSERVATIONAL","This PMCF study \"VOLTAIRE-AF\" will allow to observe acute and long-term safety and performance outcomes of the last generation of Volta Medical AI software (Volta AF-Xplorer II) during AF ablation using next-generation mapping and ablation technologies over a 24-month follow-up and in \"real life\"clinical practice, without any imposed clinical workflow.",[25,26,27],"Atrial Fibrillation","Atrial Arrhythmia","Arrhythmias, Cardiac",[29,30,31,32,33,34,26],"Volta AF-Xplorer II","Artificial Intelligence","Cardiac ablation","Medical Device","Software","Volta Medical","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-22","ACTUAL",{"date":41,"type":39},"2026-06-16",{"date":43,"type":21},"2030-06",{"name":34,"class":45},"INDUSTRY",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100520415","clinical-and-healthcare-outcomes-from-real-world-use-in-the-united-states-of-a-companion-ai-during-af-ablation-100520415","NCT06056271","Clinical and Healthcare Outcomes From Real-World Use in the United States of a Companion AI During AF Ablation","COMPANION AI","Inclusion Criteria:\n\n1. Patients 21 years of age or older who is:\n\n   * indicated for AF ablation or\n   * Who has received an AF-ablation with the past 24 months where VX1 was used or\n2. Patients are receiving or received a catheter ablation procedure for AF according to current guidelines\n3. Patients must be able and willing to provide written informed consent to participate in the clinical trial\n\nExclusion Criteria:\n\n1. Patients not indicated or were not indicated for catheter ablation according to current guidelines\n2. Patients with AF secondary to an obvious reversible cause\n3. Patients who are or may potentially be pregnant\n4. Enrollment in an investigational study evaluating another non-VX1 investigational device, biologic, or drug","21 Years",{"count":55,"type":21},400,"Observational, multi-center, clinical device registry for US patients with a primary goal to observe the clinical outcomes in patients who are mapped with Volta Medical's VX1 or AF-Xplorer systems during AF ablation procedures.",[25],"2025-12-02",{"date":60,"type":39},"2025-12-10",{"date":62,"type":39},"2024-03-19",{"date":64,"type":21},"2027-12",{"name":34,"class":45},4,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100579500","long-term-evaluation-of-tailored-vs-anatomical-ablation-strategy-for-persistent-atrial-fibrillation-100579500","NCT06825104","Long-Term Evaluation of TAILORED Vs Anatomical Ablation Strategy for Persistent Atrial Fibrillation","TAILORED-LT","Inclusion Criteria:\n\n* Patient who participated in the Tailored AF study\n* Patient not withdrawn during the 12-month follow-up period post-index procedure in the Tailored AF study\n* Patient able and willing to provide written informed consent to participate in this extension Tailored-LT study\n\nExclusion Criteria:\n\n* Person deprived of liberty or under guardianship\n* Person unable to undergo a medical monitoring for geographical, social or psychological reasons",{"count":75,"type":21},278,"The TAILORED-LT study is conducted as an extension follow-up until 5 years of the initial TAILORED-AF study (NCT04702451), in order to demonstrate the long-term superiority in terms of freedom of atrial fibrillation (AF) of a tailored ablation strategy targeting areas of spatio-temporal dispersed electrograms in combination with pulmonary veins isolation (PVI) over an anatomical ablation strategy targeting PVI alone for the initial ablation procedure of persistent AF.",[25],[30,79,80,32,81,34,33],"VX1","Volta AF-Xplorer","Cardiac Dispersion","2025-03-10",{"date":84,"type":39},"2025-03-13",{"date":86,"type":39},"2025-03-06",{"date":88,"type":21},"2027-12-31",{"name":34,"class":45},13,""]